Cullgen Inc.
United States
- San Diego, California
- 09/05/2023
- Unknown
- $40,000,000
Cullgen is a biopharmaceutical company that has developed protein degradation technology that utilizes the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Our technology, which we call uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) has the potential to address a broad range of intracellular disease targets, including those representing the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to as undruggable targets. In addition to using our uSMITE™ platform to build our own pipeline of protein degradation product candidates, we are also developing a portfolio of novel E3 ligands. You can learn more information about Cullgen on our website: www.Cullgen.com
- Industry Biotechnology Research
- Website https://www.cullgen.com/
- LinkedIn https://www.linkedin.com/company/cullgen/
Findd.AI | $21,000,000 | (May 22, 2026)
CVRD Health | $5,000,000 | (May 22, 2026)
checker | $8,000,000 | (May 22, 2026)
Oorja Bio | $30,000,000 | (May 22, 2026)
Neurosoft Bioelectronics | $7,500,000 | (May 22, 2026)
Imperagen | $5,000,000 | (May 22, 2026)
Hark(1) | $700,000,000 | (May 22, 2026)
Dandelion Health | $14,000,000 | (May 22, 2026)
Century Health | $5,000,000 | (May 22, 2026)
shatterdome energy | $3,500,000 | (May 22, 2026)
LawX | $8,709,375 | (May 22, 2026)
Overwatch AI | $1,500,000 | (May 22, 2026)
Tribal(1) | $10,000,000 | (May 22, 2026)